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Abstract: Photoacoustic imaging (PAI) and thermoacoustic imaging (TAI) are two emerging 
biomedical imaging techniques that both utilize ultrasonic signals as an information carrier. 
Unique advantages of PAI and TAI are their abilities to provide high resolution functional 
information such as hemoglobin and blood oxygenation and tissue dielectric properties 
relevant to physiology and pathology. These two methods, however, may have a limited 
detection depth and lack of endogenous contrast. An exogenous contrast agent is often needed 
to effectively resolve these problems. Such agents are able to greatly enhance the imaging 
contrast and potentially break through the imaging depth limit. Furthermore, a receptor-targeted 
contrast agent could trace the molecular and cellular biological processes in tissues. Thus, 
photoacoustic and thermoacoustic molecular imaging can be outstanding tools for early 
diagnosis, precise lesion localization, and molecular typing of various diseases. The agents 
also could be used for therapy in conjugation with drugs or in photothermal therapy, where 
it functions as an enhancer for the integration of diagnosis and therapy. In this article,  
we present a detailed review about various exogenous contrast agents for photoacoustic  
and thermoacoustic molecular imaging. In addition, challenges and future directions of 
photoacoustic and thermoacoustic molecular imaging in the field of translational medicine 
are also discussed. 
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1. Introduction 
Photoacoustic imaging (PAI) is a burgeoning biomedical structural and functional imaging technique 
which utilizes ultrasonic signals as an information carrier that captures information about optical 
absorption property relevant physiology and pathology inside tissues. The basic process of the PAI 
excitation source is summarized below: (1) the tissue absorbs light energy after being irradiated by visible 
light or near-infrared light; (2) the absorber produces adiabatic expansion that induces photoacoustic 
signals [1]; (3) the transducers detect the signals; (4) a data acquisition card stores up information for 
image reconstruction analysis. PAI has a high contrast and resolution for the combination of excellent 
selectivity of optical imaging and high penetration of ultrasonic imaging. The image resolution and 
maximum imaging depth can be adjusted with the ultrasonic frequency and the penetration of diffuse 
photons. PAI has a close relationship with optical properties, thermal properties and acoustic properties 
of biological tissue. PAI incorporates biochemical information, physical characteristics, metabolic 
status, pathological changes and even neural activity because the spectrum of tissue is related to the 
molecular structure. For instance, PAI is suitable for applications in vascular structural and functional 
imaging or tumor imaging due to the ability to acquire hemoglobin information. So far, several variations 
of photoacoustic imaging have been developed, including Photoacoustic Spectroscopy (PAS), 
Photoacoustic Tomography (PAT), Photoacoustic Microscopy (PAM), and Photoacoustic Endoscopic 
imaging (PAE) [2,3]. 
Thermoacoustic Imaging (TAI) is another emerging biomedical imaging technique. Broadly defined, 
TAI is an application of the photoacoustic effect. Unlike PAI, a TAI excitation source involves far-infrared 
light or microwaves. It also provides longer imaging depth due to a different electromagnetic radiation. 
TAI offers higher spatial resolution than microwave imaging and receives much deeper imaging than 
most optical imaging techniques [4]. Since it is based on a different absorption mechanism, TAI can 
capture information about dielectric properties (such as the distributional difference of some polar molecules 
and ions) of the relevant physiology and pathology inside of tissues. TAI could potentially be used for 
early cancer detection and foreign bodies’ detection [5]. Therefore, the advantages of PAI and TAI over 
other imaging modalities will be likely to make the application of these two techniques in clinical 
medicine more feasible and practical. 
There are several major endogenous contrast agents used in PAI, including hemoglobin, melanin, 
lipid and water in tissues. TAI is usually performed by using the distributional difference of water content 
and ions’ concentration. In the situation where a limited detection depth is certain or an endogenous 
contrast is not available, an exogenous contrast agent can be utilized to effectively resolve these 
problems. Oral or injectable chemicals, known as exogenous contrast agents, can be used to enhance 
images in medical scans of the tissues or organs. Besides improve resolutions, they can also potentially 
break through the imaging depth limit. Furthermore, a receptor-targeted contrast agent can trace the 
molecular and cellular biological processes in tissues. Thus, photoacoustic and thermoacoustic imaging 
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can be outstanding tools for early diagnosis, precise lesion localization and molecular typing of various 
diseases. A targeted contrast agent can also be used for therapy in conjugation with drugs or photothermal 
therapy, and the double virtues of imaging and targeted therapy will then be possessed. 
2. Exogenous Contrast Agents 
With the development of novel imaging technologies, contrast agents have played an important role 
in molecular imaging. There are various principles, materials, shapes, and sizes of contrast agents suitable 
for different imaging modalities. Ideal contrast agents could significantly increase contrasts, effectively 
improve imaging depth or accuracy, and provide molecular specific information. For instance, systemic 
delivery of the nanoprobe into the mice bearing mammary tumors led to a significant improvement in 
the photoacoustic signals and enabled PAI of tumors located as deep as 31 mm beneath the tissue  
surface [6]. The recent surge of interest has expanded the depth of TAI techniques with exogenous 
contrast agents to biomedical imaging, such as breast cancer imaging, foreign body detection, and targeted 
tumor detection [4]. Some contrast agents have a passive-targeting ability, that is, they can extravasate 
into tumor tissues because of impaired vasculature and the enhanced permeability and retention (EPR) 
effect in solid tumors. Other contrast agents conjugated with a molecular probe (such as antibodies, 
proteins, nucleic acids and peptides) possess an active-targeting ability. As ligands, they bind to a specific 
subset of receptors in target cells or tissues. They may also act as drug carriers by significantly enhancing 
the drug delivery to lesions. In such a role, the efficacy of the drug is improved while the side effects are 
reduced due to substantial alterations in the drug’s distribution and metabolism. From a translational 
standpoint, further research on exogenous contrast agents is of great importance in order to transform 
photoacoustic and thermoacoustic molecular imaging research into clinical applications. 
2.1. Contrast Agents for PAI 
In this section, a detailed review about various exogenous contrast agents for photoacoustic molecular 
imaging is presented. In Table 1, they are divided into five types, which are classified by principle and 
function, including dyes, plasmonic nanoparticles, various new class nanoparticles, multimodality contrast 
agents, and theranostic contrast agents. 
2.1.1. Dyes 
Dyes are the first class of photoacoustic contrast. Most of them are nanometer scale fluorescent 
molecules which can be readily removed by the urinary system. Indocyanine-green (ICG), for example, 
is an FDA approved fluorescent contrast agent that can be used for both fluorescence and photoacoustic 
imaging. It absorbs light primarily in the range of 600–900 nm and emits fluorescence light from  
750–950 nm. Wang, et al., utilized ICG of various concentrations, sizes, and depth locations, along with 
PAT and Fluorescence Molecular Tomography (FMT) in an experiment involving a target embedded in 
a background phantom. Their results found that when ICG is administered in combination with high 
resolution PAT and high sensitivity FMT, a better diagnostic tool is created. The efficiency of a contrast 
agent coupled with these tools therefore demonstrates a potential for clinical applications in the future [7]. 
A second dye that functions as an effective contrast agent is Alexa Fluor 750, a common near-IR 
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fluoescent dye. Razansky, et al., showed that the depth-resolved distribution of flurochromes, Alexa 
Fluor 750, in small animals can be imaged with 25 fmol sensitivity and 150 μm spatial resolution by 
multispectral photoacoustic imaging [8,9]. Another effective agent, Evans blue contrast dye, was imaged 
by Li, et al., in order to see its wash-in process in cortex vasculature. This dye can tightly bind to serum 
albumin in the vasculature and has been used to determine blood volume in a study of the blood-brain 
barrier [10]. Finally, Yang, et al., developed a novel near-infrared dye-based imaging caspase-9 probe 
that directly detects apoptosis with a high specificity in cancer cells by PAI [11]. It should be noted that 
there are many other dyes used in PAI, including BHQ3, QXL680 [12], IRDye800CW [13], MMPSense™ 
680 [14] and Methylene blue [15]. 
Table 1. Contrast agents for photoacoustic imaging. 
Photoacoustic 
Contrast Agent 
Type 
Absorption 
Peak (nm) 
Size (nm) 
Modification 
Application 
Application Ref. 
Indocyanine-green 
NIR Fluorescent 
Dye 
810 <2 
CarbonNanotube, PEG, 
PEBBLEs 
PAT, in tissue 
phantoms and  
in vivo 
[7,16–19] 
Methylene blue 
NIR Fluorescent 
Dye 
650–700 <2  
PAT, in tissue 
phantoms 
[15] 
Alexa Fluor 750 
NIR Fluorescent 
Dye 
750 <2  
Multispectral PAI, 
in vivo 
[8,9] 
IRDye800CW 
NIR Fluorescent 
Dye 
750–800 <2 NPR-1 PAS, in vivo [13] 
IRDye800-
c(KRGDf) 
NIR Fluorescent 
Dye 
750–790 <2 Integral proteinαvβ3 PAS, in vivo [20] 
Evans Blue 
NIR Fluorescent 
Dye 
550 <2  PAT, in vivo [10] 
PPCy-C8 
NIR Fluorescent 
Dye 
754–789 <2 Perfluorocarbon 
In vivo,  
dual-modality  
PAI-FI 
[21] 
Cypate-C18 
NIR Fluorescent 
Dye 
754–790 <2 Perfluorocarbon 
In vivo,  
dual-modality  
PAI-FI 
[21] 
Caspase-9 Probe 
NIR Fluorescent 
Dye 
640 <2  PAI, in vivo [11] 
MMPSence™ 680 
NIR Fluorescent 
Dye 
620, 680 <2  
PAI, in tissue 
phantoms 
[14] 
BHQ3 Quencher 672 <2  PAI, in vitro [12] 
QXL680 Quencher 680 <2  PAI, in vitro [12] 
Au Nanospheres 
Plasmonic Noble 
Metal 
Nanoparticle 
520–550 20–80 PEG PAT, in vivo [22,23] 
Au Nanoshells 
Plasmonic Noble 
Metal 
Nanoparticle 
700–1100 50–500 PEG PAT, in vivo [24,25] 
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Table 1. Cont. 
Photoacoustic 
Contrast Agent 
Type 
Absorption 
Peak (nm) 
Size (nm) 
Modification 
Application 
Application Ref. 
Au Nanorods 
Plasmonic Noble 
Metal 
Nanoparticle 
550–1550 
a few to 
hundreds 
of  
HER2, EGFR PAI, in vitro [26–28] 
Au Nanocages 
Plasmonic Noble 
Metal 
Nanoparticle/ 
Theranostic 
Contrast Agent 
820 25  
PAT, in vivo, 
photothermal 
therapy 
[29–31] 
Au Nanoclusters 
Plasmonic Noble 
Metal 
Nanoparticle 
500–550 100  PAI, in vitro [32,33] 
Au Nanostars 
Plasmonic Noble 
Metal 
Nanoparticle 
767 120  PAT, in vivo [34,35] 
Au Nanobeacons 
Plasmonic Noble 
Metal 
Nanoparticle 
520 150 αvβ3 PAT, in vivo [36,37] 
Ag Nanoplates 
Plasmonic Noble 
Metal 
Nanoparticle 
550–1080 25–218 a-EGFR, PEG PAI, in vivo [38] 
Ag Nanosystems 
Plasmonic Noble 
Metal 
Nanoparticle/ 
Theranostic 
Contrast Agent 
400–500 180–520  
PAI, ex vivo;  
image-guided 
therapy 
[39] 
Quantum dots 
Nanoparticles 
Based On Other 
Principles 
400–750 <10  
PAT, in vivo:  
Triple-modality  
PA-PT-Fluorescent 
[40] 
Nanodiamond 
Nanoparticles 
Based On Other 
Principles 
820 68.7  PAI, in vivo [41] 
Polypyrrole 
Nanoparticles 
Nanoparticles 
Based On Other 
Principles 
700–900 46  PAI, in vivo [42] 
Copper Sulfide 
Nanoparticles 
Based On Other 
Principles 
900 11 ± 3  PAI, in vivo [43] 
Graphene 
Nanosheets 
Nanoparticles 
Based On Other 
Principles 
200–900 10  PAI, in vitro [44] 
Iron Oxide-gold 
Core-shell 
Multimodality 
Contrast Agent 
660–900 1–5  
Triple-modality 
MRI-PAI-mmPA 
[45] 
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Table 1. Cont. 
Photoacoustic 
Contrast Agent 
Type 
Absorption 
Peak (nm) 
Size (nm) 
Modification 
Application 
Application Ref. 
Gd2O3 
Multimodality 
Contrast Agent 
 100 DEG, gelatin 
In vivo,  
dual-modality  
PAT-MRI 
[46] 
Single-walled 
Carbon Nanotubes 
(SWNT) 
Multimodality 
Contrast Agent 
785 5–8 Protamine, PEG 
In vivo,  
Triple-modality 
Raman- MRI-PAI 
[47] 
Dye-loaded 
Perfluorocarbon-
based Nanoparticles 
Multimodality 
Contrast Agent 
750–800 220 ± 11 
cypate-C18,  
PPCy-C8,PEG2000,  
phosphatidylethanolamine 
In vivo,  
dual-modality  
PAI-FI 
[21] 
AuMBs 
Multimodality 
Contrast Agent 
760 100–1000 HAS 
Dual-modality  
PAI-UI 
[48] 
Triggered 
Nanodroplets 
Multimodality 
Contrast Agent 
750–800 300 Perfluorocarbon 
In tissue phantoms 
and in vivo,  
dual-modality  
PAT-UI 
[49] 
Cobalt 
Nanowontons 
Multimodality 
Contrast Agent 
700 30–90  
Dual-modality  
MRI-PAT 
[50] 
Nanoroses 
Multimodality 
Contrast Agent 
700–850 30  PAI, in vitro [51] 
MPRs 
Theranostic/ 
Multimodality 
Contrast Agent 
532 120 maleimide-DOTA-Gd 
In vivo,  
triple-modality  
MRI-API-Raman; 
image-guided 
surgery 
[52] 
Goldsilica Core 
shell Nanorods 
Theranostic 
Contrast Agent 
780 10.3 ± 1.1 PEG PAI, in vitro [53,54] 
Superparamagnetic 
Iron Oxide (SPIO) 
Theranostic 
Contrast Agent 
500–780 80–150  PAI, ex vivo [55] 
Dyes can also be surface-modified or conjugated with other contrast agents. Li, et al., used PAS to 
obtain high resolution images of the distribution of IRDye800-c(KRGDf) targeting integrin αvβ3 
overexpressed in human U87 glioblastomas in nude mouse brains. Simultaneously, the hemoglobin 
oxygen saturation and the total hemoglobin concentration of the vasculature which revealed hypoxia in 
tumor neovasculature were obtained [20]. Akers, et al., explored perfluorocarbon-based nanoparticles by 
incorporating two different NIR fluorescent dyes, PPCy-C8 and cypate-C18, as PA and fluorescence 
imaging agents. They demonstrated the contrast agent’s ability of lymph node mapping with both 
modalities [21]. Besides these surface-modified dyes, there are many other dyes developed for PAI, such 
as Indocyanine-green-embedded PEBBLEs [16], ICG-PEG [17], ICG-enhanced carbon nanotubes [18], 
and ICG encapsulated in virus-mimicking nanoconstructs [19]. 
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2.1.2. Plasmonic Noble Metal Nanoparticles 
Noble metal nanoparticles have been widely used as photoacoustic contrast agents due to their intrinsic 
optical absorption, surface plasmon resonance (SPR), effective surface modification, and high technical 
maturity of preparation. It is well-known that the plasmon resonance of metal nanoparticles is highly 
sensitive to the nanoparticle size, shape, and dielectric properties of the surrounding medium [56,57]. 
Usually, the optical absorption of noble metal nanoparticles is a few orders of magnitude larger than that 
of traditional dyes. There are essentially two types of noble metal nanoparticles used in PAI: gold 
nanoparticles and silver nanoparticles. 
The optical properties of gold nanoparticles can be readily tuned by varying their size and shape. 
Their relative scattering to absorption contribution could be easily tuned by a change in their dimensions. 
There are a trend that larger nanoparticles would be more suitable for biological cell imaging applications 
based on light scattering, while those in the intermediate size range would generate more optical-to-acoustic 
conversion and then serve as excellent photoabsorbers for laser photothermal therapy and applications 
based on absorption contrast [57]. The optical-to-acoustic conversion efficiency represents how many 
incident photons will be absorbed and converted to heat and how fast this heat can diffuse from the target 
during thermoelastic expansion and wave generation. As such, this conversion efficiency will determine 
the contrast intensity of photoacoustic imaging [6]. These nanoparticles thus exist in a variety of shapes 
and sizes: Au nanosphere, Au nanoshell, Au nanorod, Au nanocage, Au nanocluster, Au nanostar, Au 
nanobeacon, andso on. To begin with, Au nanospheres consist of one important categorization of 
nanoparticles. The common size range employed (approximately 40 nm) is able to display an absorption 
cross-section five orders higher than any conventional absorbing dyes. In contrast, the magnitude of light 
scattering by 80-nm gold nanospheres is 5 orders higher than light emissions from strongly fluorescing 
dyes. It can be seen then that absorption wavelength will increase with size. Unfortunately, the plasma 
resonance absorption peak of nanospheres (520–550 nm) is too limited to be of any use for in vivo 
applications [57–59]. However, Zhang, et al., have evaluated the ability of systemically administered 
poly(ethylene glycol)-coated (PEGylated) gold nanoparticles as a contrast agent for in vivo tumor 
imaging with PAT. They have properly demonstrated that the accumulation of gold nanoparticles in 
tumors, due to EPR effects, can be efficiently imaged with PAT. These experiments were conducted via 
IV administration of these nanoparticles into tumor-bearing mice (as shown in Figure 1) [22,23]. The 
next classification involves the Au nanoshell, which is an optically tunable nanoparticle consisting of a 
dielectric core (silica) surrounded by a thin metallic layer (gold). Au nanoshells have optical cross-sections 
comparable to and even higher than Au nanospheres. By increasing the total nanoshell size or the ratio 
of the core-to-shell radius, the resonance wavelength of nanoshells can be precisely and systemically 
controlled over a broad spectrum, including the near-infrared region where optical transmission occurs 
through biological tissues.Wang, et al., has used PAT to image in vivo distributions of poly(ethylene 
glycol)-coated nanoshells circulating in the vasculature of a rat brain. Their results show that optical 
absorption in the brain vessels was enhanced by up to 63% after three sequential administrations of such 
nanoshells [24,25]. Third, Au nanorods are yet example of an excellent photoacoustic contrast agent. 
They are able to display optical cross-sections comparable to nanospheres and nanoshells, however, at a 
much smaller effective size. Their optical resonance can be linearly tuned across the near-infrared region 
by changing either the effective size or aspect ratio of the nanorods. Gold nanorods show per micron 
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absorption and scattering coefficients that are an order of magnitude higher than those of nanoshells and 
nanospheres [26,27]. Li, et al., conducted studies involving HER2, EGFR, and CXCR4 as the primary 
target molecules binding to Au nanorods in order to examine two types of cancer cells, OECM1 and 
Cal27. OECM1 cells overexpressed HER2, but exhibited a low expression of EGFR, whereas Cal27 
cells showed the opposite expression profile. Single and double targeting resulted in signal 
enhancements of up to 3 dB and up to 5 dB, respectively, and therefore a potential in improving cancer 
diagnoses has been portrayed [28]. Next, an Au nanocage is a type of cage-like multihollow optically 
tunable nanoparticles. Yang, et al., were able to sequentially inject poly(ethylene glycol)-coated Au 
nanocages into the circulatory system of a rat in three administrations. In vivo PAT was conducted 
immediately prior to the first injection and performed continuously until 5 h after the final injection. 
Results show that a gradual enhancement of the optical absorption in the cerebral cortex, by up to 81%, 
was observed over the course of the experiment [29–31]. Shortly after the success of Yang, et al.,  
Yoon, et al., developed a kind of photoacoustic contrast agents named “biodegradable nanoclusters”, 
which consist of sub-5 nm primary gold nanoparticles stabilized by small amountsof biodegradable 
polymer. The nanocluster assembly is controlled by a weakly adsorbing biodegradable polymer  
through a combination of electrostatic, and depletion forces [32,33]. The sixth category of noble metal 
nanoparticles involves star-shaped gold nanoparticles (“nanostars”). These stars have plasmon bands 
that are tunable into the NIR region. The structure contains multiple sharp branches that act as “lightning 
rods” that greatly enhance the local EM-field. The plasmon resonant wavelength correlates with the 
branching [34]. Kim, et al., demonstrated that the high photoacoustic sensitivity of nanostars enable their 
in vivo detection in rat sentinel lymph nodes and vessels, suggesting a direct application toward lymph 
angiography [35]. Besides nanostars, gold nanobeacons (GNB) represent another effective contrast 
agent. Such beacons have a robust nanoparticle platform that entraps multiple copies of tiny gold 
nanoparticles (2–4 nm) within a larger colloidal particle encapsulated by biocompatible synthetic or 
natural amphilines. The utilization of numerous small gold particles significantly amplify the  
signal without exceeding the renal elimination threshold size (as shown in Figure 2) [36,37]. For the 
purposes of angiogenesis, an essential microanatomical biomarker of tumor and cardiovascular disease 
progression, integrin-targeted GNBs allows for visualization of numerous angiogenic sprouts and bridges. 
Finally, the last class of noble metal nanoparticles consists of silver nanoplates, which possess  
good stability, biocompatibility, and a low toxicity. Their use as a photoacoustic contrast agent can  
also be easily functionalized for molecular photoacoustic imaging in vivo. Once conjugated to a-EGFR, 
functionalized nanoplates underwent receptor-mediated endocytosis in pancreatic cancer cells that 
overexpress EGFR, demonstrating their potential for molecular specificity in vitro [38]. Similarly,  
a nanosystem consists of a porous silver layer deposited on the surface of spherical silica cores ranging 
in diameter from 180–520 nm (see in Figure 3). The porous nature of the silver layer allows for the 
release of drugs or other therapeutic agents encapsulated within the core for future applications. In their 
current PEGylated form, the silver nanosystem is shown to be nontoxic in vitro at concentrations of 
silver up to 2 mg/mL [39]. 
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Figure 1. PAT images of tumor at 5 min (a) and 5 h (b) following tail vein injection of  
gold nanoparticles; (c) and (d) are the subtraction PAT images of tumor following tail vein 
injection of gold nanoparticles demonstrating increased accumulation of nanoparticles in 
tumor at 5 h. The color scale (right) represents optical absorption of tissue (arbitrary units); 
(e) is gross picture of tumor in mouse and (f) is the fusion image of gross photo and subtraction 
PAT image, 5 h following tail vein injection. (Reprinted from reference [22]. Copyright with 
permissionfrom © 2009 IOP Publishing Ltd.). 
 
2.1.3. Nanoparticles Based on Other Principles 
Besides noble metal nanoparticles, there are others based on different principles. Quantum dot (QD) 
is an example of an exciting new class of nanoparticles composed of II-VI or III-V group elements.  
It has unique optical properties, such as relatively high quantum yields, broad excitation spectra ranging 
from ultraviolet to near-infrared, and relatively narrow emission spectra. It has been demonstrated that 
the application of QDs provide an opportunity for multimodal high resolution (300 nm) PA-PT-fluorescent 
imaging to flourish. Hybrid multilayer QDs, which have optimized absorption, thermal, and acoustic 
properties, may also be utilized in PT therapy. In this scenario, they function as enhancers of the conversion 
of laser energy in PT, PA, and bubble phenomena [40]. 
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Figure 2. In vivo noninvasive photoacoustic imaging of sentinel lymph nodes in rat  
(λ = 767 nm). (a–g) Scale bar is 5 mm. Aliquots of 150 mL of nanobeacons were injected 
intradermally in all cases. GNB-M: (a) control PA image; (b) 5 min post-injection image of 
GNB-M (5 mM); GNB-L: (c) control PA image; (d) lymph node is not visible in a 60 min 
post-injection image of GNB-L (680 nM); GNB-S: (e) sagittal maximum amplitude projection 
(MAP) pre-injection control image; bright parts represent optical absorption from blood 
vessels, marked with red arrows; (f) PA image (MAP) acquired 5 min after GNB-S injection 
(10 nM); SLNs are clearly visible, marked with green arrows; lymphatic vessel is also 
visible, marked with blue arrows; (g) 20 min post-injection PA image. (Reprinted from 
reference [37]. Copyright with permission from © 2011 John Wiley & Sons, Ltd.). 
 
Figure 3. Multifunctional nanosystem platform capable of providing imaging contrast, drug 
delivery, and image-guided therapy. (Reprinted from reference [39]. Copyright with 
permission from © 2010 Society of Photo-Optical Instrumentation Engineers). 
 
Radiation-damaged nanodiamonds (DNDs) are another set of potentially ideal optical contrast agents 
for PAI in biological tissues due to their low toxicity and high optical absorbance. In a set of studies, 
Zhang, et al., were able to create new DNDs which produced a 71-fold higher PA signal on a molar basis 
in comparison to similarly dimensioned gold nanorods. 7.1 fmol of DNDs injected into rodents could be 
clearly imaged 3 mm below the skin surface with a PA signal enhancement of 567% [41]. A third type 
of nanoparticles involves polypyrrole nanoparticles (PPy NPs), novel organic PAT contrast agents. 
Monodisperse PPy NPs are about 46 nm in diameter with strong absorption in the near-infrared (NIR) 
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range, which allows for visualization of PPy NP-containing agar gel embedded in a chicken breast 
muscle at a depth of about 4.3 cm. In comparison with PAT images based on the intrinsic optical contrast 
in mice, PAT images (within 1 h) following intravenous administration of PPy NPs showed the brain 
vasculature with greater clarity than hemoglobin in blood [42]. Next, semiconductor copper sulfide 
nanoparticles (CuS NPs) are also used effectively in PAI. The average diameter of a CuS NP was 11 ± 3 nm. 
The absorption peaked at around 990 nm. CuS NPs allowed for visualization of a mouse brain after 
intracranial injection, rat lymph nodes 12 mm below the skin after interstitial injection, and CuS  
NP-containing agarose gel embedded in chicken breast muscle at a depth of about 5 cm [43]. By intentionally 
excluding KMnO4 and exploiting pure nitronium ion oxidation, aided by the unique thermal and kinetic 
effects induced by microwave heating, graphite particles can be converted into microwave-enabled low 
oxygen grapheme (ME-LOGr) nanosheets with their π-conjugated aromatic structures and properties 
largely retained. Without the need of any postreduction processes to remove the high concentration of 
oxygenated groups that results from Hummers graphene oxide (GO) formation, the graphene nanosheets 
as-fabricated exhibited strong absorption and high photothermal. Patel, et al., demonstrated that strong 
photoacoustic signals can be generated from these graphene nanosheets with NIR excitation (see in 
Figure 4). The photo-to-acoustic conversion is weakly dependent on the wavelength of the NIR excitation, 
which is different from all other photoacoustic contrast agents previously reported. From these results, 
it can be seen that these NPs possess great potential as nanocarriers to develop multifunctional drug 
delivery systems with on an “on demand” release. They may also be used for in vivo photoacoustic 
imaging capabilities for in situ evaluation of therapeutic effects and tracking their long term fate [44]. 
Figure 4. Photoacoustic (PA) signal of GO and ME-LOGr nanosheets of different 
concentrations, illuminated with 700 (a) and 800 (b) nm laser. The color coded vertical bar 
represents the strength of the photoacoustic signal generated. GO nanosheets were obtained 
via control-A experiment where nitronium ions and KMnO4 both act as an oxidant. (Reprinted 
from reference [44]. Copyright with permission from © 2013 American Chemical Society). 
 
2.1.4. Multimodality Contrast Agents 
No mono-modality imaging can obtain all the information needed in biomedical imaging technologies. 
The preponderance complementarity of various imaging modes, multimodal imaging, will greatly 
improve medical high-tech. So far, there have been many imaging technologies used in combination 
with PAI. To begin with, ultrasound imaging (UI) has low test fees, is easy to operate, and can track in 
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real-time. However, it has a low sensitivity and cannot detect lesions early due to its inability to distinguish 
adsorbers which have the same acoustic impedance but different dielectric properties. Next, magnetic 
resonance imaging (MRI) has a high resolution of soft tissues and maps macrostructure well, but is 
unable to differentiate benign from malignant tumours or track in real-time due to its long scan time.  
On the other hand, fluorescence imaging (FI) has a high sensitivity, can track in real-time and monitor 
dynamically, but cannot capture information in deep tissue because of a limited penetration; Raman 
imaging allows for highly specific and sensitive detection of surface-enhanced Raman scattering contrast 
agents, as well as the multiplexing of multiple agents in living subjects. Thus, the combination of PAI 
and examples of the above technology will prove to be a comprehensive source of information for 
structural and functional physiology and pathology. 
Although every individual imaging modality has its own contrast agents, multimodality imaging 
needs multimodality contrast agents. Magnetic nanoparticles are a category of such agents that have 
been widely applied in biomedicine. Gold-iron oxide composite nanoparticles, for example, open up vast 
possibilities to MRI-PAI dual-modal technology [6,60,61]. Jin et al., demonstrated that multifunctional 
iron oxide and gold-coupled core-shell nanoparticles (NPs), with well-defined structural characteristics 
and physical properties not only offer contrast for electron microscopy, MRI, and scattering-based imaging 
but, more importantly, enable a new imaging mode, magnetomotive photoacoustic imaging. This type 
of imaging displays a remarkable contrast enhancement compared with photoacoustic images using only 
conventional nanoparticles contrast agents [45]. Gold-speckled Gd2O3 nanoparticles and rare earth-doped 
Gd2O3 nanorods have also been used for optical and MR imaging. Kimura, et al., synthesized and 
isolated new size-controlled and biocompatible Gd2O3-DEG-gelatin nanoparticles as a bimodal contrast 
agent for use in PAI and MRI (see in Figure 5) [46]. 
Figure 5. PAT-MRI images of tumor (a) before and (b) after injection of Gd2O3-DEG-gelatin. 
(Reprinted from reference [46]. Copyright with permission from © 2012 WILEY-VCH 
Verlag GmbH & Co. KGaA, Weinheim). 
 
Another type of multimodality contrast agents are single-walled carbon nanotubes (SWNTs) which 
have broad absorption that can produce strong photoacoustic signals. They possess surface modification 
and biocompatibility similar to plasmonic nanoparticles. Wang, et al., have used such SWNTs to  
develop a novel approach in labeling human mesenchymal stem cells (hMSCs) with polyethylene glycol 
(PEG) functionalized SWNTs conjugated with protamine (SWNT-PEG-PRO) for in vivo tracking by  
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Raman-MRI-PAI triple-modal imaging [47]. Microbubbles (MBs), which can be composed of 
phospholipids, albumin, or polymer, have also been used clinically. Gas-filled MBs can produce strong 
acoustic scattering relative to the surrounding tissue. AuMBs comprise albumin-shelled microbubbles 
with encapsulated gold nanorods. They were investigated as a photoacoustic/ultrasound dual-modality 
contrast agent [48]. Wilson, et al., introduced an exogenous contrastagent entitled, “triggered nanodroplets” 
consisting of liquid perfluorocarbon nanodroplets with encapsulated plasmonic nanoparticles that utilize 
vaporization for photoacoustic signal generation. Through such means, they provide significantly higher 
signal amplitudes than that from the traditionally used mechanism: thermal expansion. Upon pulsed laser 
irradiation, liquid perfluorocarbon undergoes a liquid-to-gas phase transition generating giant photoacoustic 
transients from these dwarf nanoparticles. Once triggered, the gaseous phase provides ultrasound contrast 
enhancement. Their results demonstrated, in phantom and animal studies, that photoacoustic nanodroplets 
can act as dual-contrast agents for both PAI and UI through optically triggered vaporization [49].  
A fourth category of agents consist of biocompatible cobalt nanowontons have a Co core and an Au  
thin-film coating. As an aside, the name is actually derived from the Chinese eatable called the wonton. 
It exhibits a combination of ferromagnetic and optical responses making it amenable to dual-modality 
MRI and PAT studies [50]. Ma, et al., reported about 30 nm stable uniformly sized NIR active, 
superparamagnetic nanoclusters (nanoroses) formed by kinetically controlled self-assembly of gold-coated 
iron oxide nanoparticles. Next, small nanoclusters with optical, magnetic, and therapeutic functionality, 
designed by an assembly of nanoparticle building blocks, offer broad opportunities for targeted cellular 
imaging, therapy, and combined imaging and therapy [51]. The MPR nanoparticle is composed of a 60-nm 
gold core covered with the Raman molecular tag trans-1,2-bis(4-pyridyl)-ethylene. The thin Raman-active 
outer layer is protected by a 30-nm silica coating further modified with maleimide-DOTA-Gd. It was 
designed as a unique triple-modality MRI-PAI-Raman imaging nanoparticle (see in Figure 6) [52]. 
Besides these nanoparticles, Dye-loaded perfluorocarbon-based nanoparticles can also be used as PAI-FI 
contrast agents [21], and CdSe core/ZnS shell quantumdots can be used as PA-PT-fluorescent [40]. 
2.1.5. Theranostic Contrast Agents 
Exogenous contrast agent can also be used for photothermal therapy, drug therapy or image-guided 
surgery. In these methods, the double virtues of imaging and targeted therapy would be possessed. They 
can be conjuncted with antibodies, proteins, nucleic acids and peptides, or drugs cluster around lesion 
points. In photothermal therapy, injections are administered and the area is irradiated by laser. Following 
this, light energy is converted into thermal energy, which can induce a rapid rise in temperature within 
the tumor. The cancer cells are killed through this method while the healthy cells are left alone. Note here 
then that the laser then is not only the excitation light source, but also the source of treatment. Chen, et al., 
have reported the ability of silica-coated gold nanorods to provide a stable photoacoustic signal, which 
implies good imaging capabilities. These nanorods thus make silica-coated gold nanorods a promising 
imaging and therapeutic nanoagent for photoacoustic imaging and image-guided photothermal  
therapy [53,54]. For the purposes of drug therapy, silver nanosystems, mentioned once above, can also 
be built with silica nanosphere coating whose optical extinction at near-infrared wavelengths is high and 
broad. Homan, et al., suggest that in future designs where drugs or other therapeutic molecules are 
encapsulated in the silica or polymeric core, this new nano platform could provide image-guided therapy 
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monitoring. This would open up a host of new applications where imaging and therapy are performed 
simultaneously [39]. Next, when Au nanocages are conjugated with anti-HER2, they are able to function 
effectively in drug treatments. Epidermal growth factor receptors are targeted in this technique since 
they overexpress on the surface of breast cancer cells (SK-BR-3). Chen, et al., showed that the nanocages 
strongly absorb light in the NIR region, with an intensity threshold of 1.5 W/cm2 to induce thermal 
destruction to the cancer cells. In the intensity range of 1.5–4.7 W/cm2, the circular area of damaged 
cells increased linearly with the irradiation power density which suggests that this new class of 
bioconjugated gold nanostructures-immuno gold nanocages can potentially serve as an effective 
photothermal therapeutic agent for cancer treatment [62]. Kircher, et al., have also designed and tested 
MPRs for a novel triple-modality strategy that combines MRI, photoacoustic imaging and Raman imaging. 
This method achieves whole-brain tumor localization for preoperative and intraoperative macroscopic 
delineation. It utilizes the high spatial resolution of MRI, three-dimensional imaging via PAI, and high 
sensitivity, specificity, and resolution of surface imaging with Raman imaging (see in Figure 7) [52]. 
Finally, Grootendorst, et al., have observed irregularities in the distribution of superparamagnetic iron 
oxide (SPIO) nanoparticles within PA imaging of nodes. A decrease in contrast then correlates with 
metastatic involvement, as seen in MR images and histology. The results therefore show that a PA based 
imaging technique may be quite valuable for nodal staging in the field of surgical oncology [55]. 
Figure 6. Triple-modality detection of brain tumors in living mice with MPRs.  
(a) Two-dimensional axial MRI, photoacoustic and Raman images. The post-injection 
images of all three modalities showed clear tumor visualization (dashed boxes outline the 
imaged area); (b) A three dimensional (3D) rendering of magnetic resonance images with 
the tumor segmented (red; top), an overlay of the three-dimensional photoacoustic images 
(green) over the MRI (middle) and an overlay of MRI, the segmented tumor and the 
photoacoustic images (bottom) showing good colocalization of the photoacoustic signal 
with the tumor. (Reprinted from reference [52]. Copyright with permission from © 2012, 
Rights Managed by Nature Publishing Group). 
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Figure 7. Intra-operative Photoacoustic imaging. A mouse bearing a glioblastoma tumor 
(primary human xenograft) was injected with MPRs (150 µL, 16 nM). After 24 h, the brain 
was perfused with PBS, excised, and embedded in an agarose gel. Coronal photoacoustic images 
were acquired before (left image) and after (right image) partial tumor resection. An absence 
of photoacoustic signal in the resected portion of the tumor was observed, while residual 
photoacoustic signal (arrow-head) was observed in the area of the non-resected tumor. Note 
that the increased grayscale ultrasound signal to the right of the resected cavity is likely due 
the surgical manipulation, an effect that is commonly observed during surgery. Photoacoustic 
images (color scale from 0 to max) were overlaid on conventional ultrasound images (gray), 
which outline the gross anatomy of the mouse brain. (Reprinted from reference [52]. 
Copyright with permission from © 2012, Rights Managed by Nature Publishing Group). 
 
2.2. Contrast Agents for TAI 
There are limited categories of thermoacoustic contrast agents. In this article, a detailed review of 
seven exogenous contrast agents for thermoacoustic molecular imaging is presented, as shown in Table 2. 
So far, none of them are approved for clinical applications, and their clinical applicability still needs to 
be properly researched. However, due to their strong magnetic field responses, efficient particle size 
distribution, and simple preparation, some magnetic nanoparticles have been applied in biomedicine  
as powerful medical diagnostic tools. The following are such examples. Carbonyl iron is one such 
microstructure agent. It has a size of 2 micrometers, strong microwave absorption, good hydrophilic and 
electromagnetic properties. It may have the potential to improve sensitivity and specificity for structural 
and functional TAI and broadly expand the capability of TAI [63]. Next, Dextran-coated Fe3O4 magnetic 
nanoparticles comprise another type of agents. They are almost spherical with diameters ranging  
from 30–50 nm. Qin, et al., investigated the feasibility of using this nanoparticle as a contrast agent in 
thermoacoustic tomography (TAT) for hepatocellular carcinoma ex vivo detection [64]. Another set of 
powerful contrast agents, in biomedicine, are comprised of paramagnetic nanoparticles due to their 
special paramagnetism, bulk effect, and high relaxations. NMG2[Gd(DTPA)] is one such paramagnetic 
ionic compound with seven unpaired electrons in the 4f orbital of the Gd3+ ion. The charged ions and 
unpaired electrons can interact with a microwave field and transform the absorbed microwave energy 
into heat. Qin, et al., verified the enhanced effect of NMG2[Gd(DTPA)] for thermoacoustic CT in vitro 
and in vivo experiments. They demonstrated that this contrast agent can increase the ionic conductivity 
and microwave absorption coefficient of tumors, thus making the boundary between tumor and normal 
tissue more obvious in TAI (see in Figure 8) [4]. 
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Table 2. Contrast agents for thermoacoustic imaging. 
Thermoacoustic 
Contrast Agent 
Type 
Excitation Source 
Frequency (GHz) 
Size(nm) 
Modification 
Application 
Application Ref. 
Carbonyl Iron 
Magnetic 
nanoparticles 
1.2 2000  
TAI, in tissue 
phantoms 
[63] 
Dextran-coated 
Fe3O4 
Nanoparticles 
Magnetic 
nanoparticles 
6 30–50 Dextran TAI, in tissue 
phantoms 
[64] 
NMG2[Gd(DTPA)] 
Paramagnetic 
ionic 
compound 
6   
TAI, in vitro and  
in vivo tumor-bearing 
mouse 
[4] 
Fe3O4/Polyaniline 
(PANI) 
Superparama
gnetic 
nanoparticles  
6 30–50 Folic Acid 
(FA) 
Ex vivo TAI in 
human blood and  
in vivo TAT in  
mouse tail, in vivo 
TAI of tumors  
[65] 
Fe3O4 /Au 
Nanoparticles 
Fe3O4 
core/Au shell 
Nanoparticles 
6 30–50 
FITC-labeled 
integrinαvβ3
mAb 
Triple-modality  
MRI-TAI-PAI  
[66] 
Single-walled 
Carbon 
Nanotubes(SWNT) 
Multimodality 
Contrast 
Agent 
3 
Diameter: 
1.2–2.2; 
length:  
500–1000 
 
In vitro, dual-modality 
PAI-TAI 
[67] 
Microbubbles 
Multimodality 
Contrast 
Agent 
3 18,000  UI, and in vitro TAI [68] 
Figure 8. Thermoacoustic CT of tumor bearing mouse before injection of NMG2[Gd(DTPA)] 
(a) and after in situ injection of NMG2[Gd(DTPA)] (b). (Reprinted from reference [4]. 
Copyright with permission from © 2012 American Institute of Physics). 
 
Yet, another compound is Fe3O4/polyaniline (PANI), which is made of superparamagnetic 
nanoparticles conjugated to folic acid (FA). These nanoparticles can then bind specifically to the surface 
of the folate receptor, a tumor marker. Nie, et al., have used a 6 GHz TAT system to successfully 
investigate that intravenous administration of the targeted nanoparticles to mice bearing tumors showed 
a five-fold greater thermoacoustic signal and a much longer elimination time than that of nontargeted 
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nanoparticles.This portrays Fe3O4/polyaniline (PANI)’s potential for its use in targeted and guided 
cancer thermal therapy (see in Figure 9) [65]. 
Figure 9. In vivo thermoacoustic imaging of tumors with contrast agent bearing in mouse. 
(a,d) TAT images of control sample injected with PBS; (b,e) TAT images of tumor injected 
with Fe3O4/PANI and Fe3O4/PANI-FA, respectively; (c,f) Photographs of tumor’s area on 
the mouse back. (Reprinted from reference [65]. Copyright with permission from © 2010 
Am. Assoc. Phys. Med.). 
 
Similarly, an Fe3O4 core can be bound to an Au shell to create Fe3O4 core/Au shell nanoparticles in 
order to combine the advantageous and highly complementary features of the Fe3O4 and gold nanoparticles. 
Zhou, et al., developed the bio-modified Fe3O4/Au NPs, which generate enhanced MR contrast and high 
photoacoustic and microwave-induced thermoacoustic signals. Such NPs can also be used for specific 
targeting and fluorescent imaging when conjugated to cancer cell targeted integrin αvβ3-positive cancer 
cells with FITC-labeled integrin αvβ3 mAb [66]. Due to its multimodality properties, single-walled 
carbon nanotubes (SWNTs) may also be utilized for TAI. Along with their intrinsic physical properties, 
they have many advantages, including their ability to encapsulate medically relevant metal ions within 
their carbon sheath, and externally functionalize the carbon sheath with a variety of imaging agents. 
Pramanik, et al., developed a novel carbon nanotube-based contrast agent for both thermoacoustic and 
photoacoustic tomography. In their study, SWNTs exhibited much more signal enhancement for 
thermoacoustic and photoacoustic signal than deionized water and blood. The large contrast enhancement 
of SWNTs was further corroborated by tissue phantom imaging studies [67]. Besides SWNTs, microbubbles 
are another multimodality agent that has been used in UI and PAI due to their echo enhancing properties 
and optical absorption properties. Microbubbles are likely to be used in TAI modalities because of their 
low microwave absorption. Mashal, et al. characterized the dielectric and acoustic properties as well as 
the thermoacoustic response of mixtures with a varying concentration of air-filled glass microbubbles in 
TAT. Microbubbles significantly lowered the microwave absorption level and increased the acoustic velocity 
of the target, which reduced both the magnitude and temporal width of the thermoacoustic response. The 
same reduction in amplitude, but a broadening of the temporal width was obtained when using organic-shell 
microbubbles [68]. 
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Finally, nano-magnetic fluid is a kind of colloid consist of nano-structured ferromagnetic particles 
disperse in the carrier liquid via a surfactant. Ferromagnetic particles conjuncted with antibodies, sulfur 
functional groups, or drugs cluster around leision points after injection, followed by microwave irradiation. 
Electromagnetic energy is then converted into thermal energy, which can induce a rise in temperature. 
This kills the cancer cells while leaving healthy cells alone. Magnetic fluid hyperthermia then could 
potentially be a meaningful application of TAI. 
3. Conclusions and Future Directions 
Effective photoacoustic or thermoacoustic contrast agents should significantly increase contrasts, 
effectively improve imaging depths or accurately provide molecular specific information. It is therefore 
prudent to follow these principles when choosing contrast agents: (1) photoacoustic or thermoacoustic 
contrast agents should be easily prepared and produced for a low cost due to future clinical applications; 
(2) the size of contrast agents has a significant impact on their distribution and drug delivery in vivo. 
Large contrast agents remain in vivo longer than small ones; however, small ones have better permeability 
than large ones. Greater permeability makes them readily enter the bloodstream and penetrate into the 
desired location after injection. Dimensional control of contrast agents exerts an important control on 
distribution and overall curative effect of drug; (3) agents should be of excellent water solubility, or they 
will be treated as foreign objects and rejected by the surrounding tissue; (4) they should be of proper 
biological compatibility and low toxicity in order to not cause adverse reactions to the tissues—the most 
major being damage to the endothelium, vascular system, blood-brain barrier (BBB), kidneys, and so on; 
(5) contrast agent should have a tendency to bind molecular probes (such as antibodies, proteins, nucleic 
acids and peptides), drugs or another contrast agent. They should have good surface modification and be 
able to effectively target specific receptors in target cells or tissues; (6) have a high stability, long half-life, 
and full dissolution in vivo in order to make them meet clinical requirements; (7) they should possess 
very good dispersibility in order to distribute evenly in the imaging region; (8) photoacoustic contrast 
agents should have a high light-to-ultrasound conversion efficiency, while thermoacoustic contrast agents 
need a high microwave-to-ultrasound conversion efficiency. Contrast agents need to be prepared and 
used discreetly in accordance with the provisions of the Food and Drug Administration (FDA). 
Despite many years of research, photoacoustic and thermoacoustic molecular imaging still has a  
lot of issues that need to be addressed promptly. The following future directions should be discussed: 
(1) There are limited categories of thermoacoustic contrast agents. Special superparamagnetism and bulk 
effect, the compounding of superparamagnetic nanoparticles, and their application in biomedicine  
will hopefully draw the attention of research fellows. Such methods show potential for the advance in 
multimodality technology of PAI, TAI and MRI; (2) The quantitative capability of photoacoustic and 
thermoacoustic molecular imaging is significant. It may help us differentiate benign from malignant 
lesions as well as obtain absolute tissue functional information. They are perhaps determinants of molecular 
typing. Besides, PAI and TAI can measure the amount of a drug at its site which will provide the theoretic 
foundation for ensuring the accuracy of injection doses for animals and patients; (3) The future research 
of contrast agents as a drug delivery system should emphasize its effectiveness and safety. The technical 
specifications of the system’s effectiveness and safety are not established yet. How to reduce toxicity 
and side effects as well as improve the drug targeting, solubility, stability, slow releasing action,  
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and how to change tissue-targeted distribution and metabolism are key issues for this research;  
(4) Mono-modality imaging cannot obtain all the information required. Compared to low resolution 
ultrasound imaging, TAI can distinguish adsorbers which have the same acoustic impedance but different 
dielectric properties. PAI is also able to capture information about optical absorption with high 
resolution. Compared to PET and SPECT, these two imaging technologies have no risk of causing injury 
by radiation. Compared to MRI, PAI and TAI have quicker imaging speed. In comparison to OCT, they 
have longer imaging depths. Overall, PAI and TAI only demands imple equipment, have low cost, and 
are easy to operate, thus they have broad and applicable prospects. The combination of TAI and PAI is 
capable of revealing information such as water and ion concentration, blood volume, and oxygenation 
of hemoglobin. The preponderance complementarity of PAI, TAI, and other imaging modes will 
significantly improve medical high-tech, which will lead to more comprehensive sources of information 
about structural and functional physiology and pathology; (5) Unfortunately, the application of 
photoacoustic and thermoacoustic contrast agents in real time imaging and their ability to confirm lesions 
before treatment cannot currently meet the needs of modern medicine. Instead, targeted drug delivery 
systems, advanced physical therapy, image guided surgery, heat therapy (e.g., high intensity focused 
ultrasound [HIFU] or radiofrequency hyperthermia), photothermal therapy, and magnet fluid hyperthermia 
are therefore the developing directionfor the future. Photoacoustic and thermoacoustic molecular imaging 
aim to integrate detection, monitoring, and reasonable treatment into one entity; (6) Contrast agent 
testings are too complicated, due to their specific animal testing experiments, longer experiment 
durations followed by clinical trials and high research and development costs. It has been concluded that 
the related research is unsystematic, has no unified standard, and is rarely used in the clinic due to various 
differences in species, individuals, and drug delivery systems. Therefore, the effectiveness and safety of 
photoacoustic and thermoacoustic molecular imaging play a key role in establishing better and more 
direct relations between basic research and clinical applications. 
Photoacoustic and thermoacoustic molecular imaging, working in tandem with powerful contrast 
agents, could provide groundbreaking opportunities for early diagnoses, precise lesion localization, 
molecular typing, drug delivery monitoring, image guided surgery, drug targeting therapy, and photothermic 
therapy of various diseases (such as cancer and cardio-cerebrovascular disorders). Photoacoustic and 
thermoacoustic molecular imaging, complemented by the development of such agents, will potentially 
bridge the gap between bench and bedside and further develop translational medicine as we know it. 
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